EPKINLY™ (epcoritamab-bysp) Approved by U.S. Food and Drug Administration as the First and Only Bispecific Antibody to Treat Ad
19/5 18:34
Company Announcement Results from phase 2 clinical trial demonstrated EPKINLY ™ (epcoritamab- bysp ) delivered 61 percent overall response rate , 38 percent complete response, and 15. 6 -month median duration of response in challenging-to-treat R/R D LBCL patients EPKINLY represents the seventh...